Literature DB >> 25738493

Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol.

Sarah Wisecup1, Shannan Eades, Syed Shahrukh Hashmi, Cheryl Samuels, Ricardo Alberto Mosquera.   

Abstract

OBJECTIVES: Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management. Our study goal was to determine prevalence and potential risk factors for hypotension development during continuous albuterol administration in pediatric patients.
METHODS: A retrospective cohort study was conducted at Children's Memorial Hermann Hospital from 1 January 2011 to 31 August 2012. A total of 152 patients admitted to pediatric intensive or intermediate care units who received continuous albuterol nebulization for management of status asthmaticus were analyzed.
RESULTS: Diastolic hypotension, defined as a value < 50 mmHg or <5th percentile of normal for age, developed in 90% of patients and a positive correlation with increasing doses of albuterol was demonstrated. The overall median time to onset of hypotension was 4 h (interquartile range (IQR): 2-6.5) and was significantly lower among patients admitted to the intensive care unit rather than intermediate care (p = 0.005). The odds of hypotension were 82% lower among patients who received fluid boluses prior to continuous albuterol nebulization. None of the potential risk factors demonstrated statistical significance.
CONCLUSIONS: Diastolic hypotension is a common occurrence among patients who receive continuous albuterol nebulization for status asthmaticus. Total albuterol dose appeared to be directly related to risk of developing diastolic hypotension. Administration of supplemental fluid boluses before continuous nebulized albuterol appeared to provide a significant protective effect. The clinical impact and the significance of diastolic hypotension and the importance of prophylactic administration of intravenous fluid boluses in patients experiencing status asthmaticus are yet to be determined.

Entities:  

Keywords:  Asthma; continuous albuterol; diastolic hypotension; status asthmaticus

Mesh:

Substances:

Year:  2015        PMID: 25738493     DOI: 10.3109/02770903.2014.1002566

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  6 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 2.  A systematic review of adverse drug events associated with administration of common asthma medications in children.

Authors:  James S Leung; David W Johnson; Arissa J Sperou; Jennifer Crotts; Erik Saude; Lisa Hartling; Antonia Stang
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240

3.  Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis.

Authors:  Prapasri Kulalert; Phichayut Phinyo; Jayanton Patumanond; Chutima Smathakanee; Wantida Chuenjit; Sira Nanthapisal
Journal:  Asthma Res Pract       Date:  2020-07-02

4.  Indicators of metabolic syndrome in normotensive normoglycemic asthmatic patients.

Authors:  Hanadi Abdelgadir Ahmed Sourg; Adil Ballal Mohammed Ahmed; Ramaze Farouke Elhakeem; Mohamed Faisal Lutfi
Journal:  J Clin Transl Res       Date:  2020-07-13

5.  Severe lactic acidosis and persistent diastolic hypotension following standard dose of intermittent nebulized salbutamol in a child: a case report.

Authors:  Marco Colombo; Anna Plebani; Annalisa Bosco; Massimo Agosti
Journal:  J Med Case Rep       Date:  2022-04-22

6.  Lactic acidosis and diastolic hypotension after intermittent albuterol nebulization in a pediatric patient.

Authors:  Tehila A Saadia; Mathew George; Haesoon Lee
Journal:  Respir Med Case Rep       Date:  2015-08-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.